Omeros (NASDAQ:OMER) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other research analysts have also weighed in on the company. ValuEngine lowered Omeros from a “buy” rating to a “hold” rating in a report on Friday, August 10th. Wedbush set a $20.00 target price on Omeros and gave the company a “hold” rating in a report on Friday, August 10th. Maxim Group lifted their target price on Omeros from $25.00 to $32.00 and gave the company a “buy” rating in a report on Friday, August 10th. Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a report on Friday, August 10th. Finally, HC Wainwright set a $34.00 target price on Omeros and gave the company a “buy” rating in a report on Monday, August 6th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $27.56.

Shares of OMER opened at $20.92 on Friday. Omeros has a fifty-two week low of $8.36 and a fifty-two week high of $25.20. The stock has a market capitalization of $860.97 million, a P/E ratio of -26.48 and a beta of 3.76. The company has a quick ratio of 3.94, a current ratio of 3.95 and a debt-to-equity ratio of -2.31.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.04). The business had revenue of $1.70 million during the quarter, compared to analyst estimates of $1.84 million. The firm’s quarterly revenue was down 90.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.33) earnings per share. sell-side analysts expect that Omeros will post -2.45 earnings per share for the current year.

In other news, VP Marcia S. Kelbon sold 4,277 shares of the business’s stock in a transaction dated Thursday, July 12th. The stock was sold at an average price of $21.48, for a total transaction of $91,869.96. Following the completion of the transaction, the vice president now owns 188,922 shares of the company’s stock, valued at $4,058,044.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Marcia S. Kelbon sold 40,723 shares of the business’s stock in a transaction dated Friday, July 27th. The stock was sold at an average price of $21.56, for a total value of $877,987.88. Following the transaction, the vice president now directly owns 219,645 shares of the company’s stock, valued at approximately $4,735,546.20. The disclosure for this sale can be found here. 12.10% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ingalls & Snyder LLC grew its holdings in shares of Omeros by 1.3% during the second quarter. Ingalls & Snyder LLC now owns 5,613,487 shares of the biopharmaceutical company’s stock worth $101,829,000 after purchasing an additional 70,625 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Omeros by 0.9% during the first quarter. BlackRock Inc. now owns 3,965,410 shares of the biopharmaceutical company’s stock worth $44,294,000 after purchasing an additional 34,832 shares in the last quarter. Cpwm LLC grew its holdings in shares of Omeros by 5.0% during the second quarter. Cpwm LLC now owns 1,074,543 shares of the biopharmaceutical company’s stock worth $19,492,000 after purchasing an additional 51,015 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Omeros during the second quarter worth about $8,513,000. Finally, UBS Group AG grew its holdings in shares of Omeros by 9.4% during the first quarter. UBS Group AG now owns 397,583 shares of the biopharmaceutical company’s stock worth $4,441,000 after purchasing an additional 34,290 shares in the last quarter. 45.94% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Article: What is a Leveraged Buyout (LBO)?

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.